Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker KROS
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Aug 18, 2026 | Annita Tanini Corp. Controller & VP, Finance | KROS Keros Therapeutics, Inc. | Sale | 1,224 | $10.29 | $12.6K Sale | Form 4 ↗ |
| Aug 18, 2026 | Esther Cho Chief Legal Officer | KROS Keros Therapeutics, Inc. | Sale | 4,485 | $10.29 | $46.2K Sale | Form 4 ↗ |
| Aug 18, 2026 | Lorena Raquel Lerner Chief Scientific Officer | KROS Keros Therapeutics, Inc. | Sale | 3,568 | $10.29 | $36.7K Sale | Form 4 ↗ |
| Aug 18, 2026 | Charles W. Newton Director | KROS Keros Therapeutics, Inc. | Sale | 551 | $10.30 | $5,675 Sale | Form 4 ↗ |
| Aug 17, 2026 | Jean Jacques Bienaime Director | KROS Keros Therapeutics, Inc. | Buy | 1,000 | $10.27 | $10.3K Buy | Form 4 ↗ |
| Jul 15, 2026 | Jean Jacques Bienaime Director | KROS Keros Therapeutics, Inc. | Buy | 1,000 | $10.61 | $10.6K Buy | Form 4 ↗ |
| Jun 15, 2026 | Jean Jacques Bienaime Director | KROS Keros Therapeutics, Inc. | Buy | 1,000 | $10.19 | $10.2K Buy | Form 4 ↗ |
| Jun 11, 2026 | Charles W. Newton Director | KROS Keros Therapeutics, Inc. | Sale | 550 | $10.04 | $5,522 Sale | Form 4 ↗ |
| Jun 4, 2026 | Julius Knowles Director | KROS Keros Therapeutics, Inc. | Sale | 2,625 | $10.73 | $28.2K Sale | Form 4 ↗ |
| Jun 4, 2026 | Nima Farzan Director | KROS Keros Therapeutics, Inc. | Sale | 2,625 | $10.73 | $28.2K Sale | Form 4 ↗ |
| Jun 4, 2026 | Alpna Seth Director | KROS Keros Therapeutics, Inc. | Sale | 2,625 | $10.72 | $28.1K Sale | Form 4 ↗ |
| May 15, 2026 | Jean Jacques Bienaime Director | KROS Keros Therapeutics, Inc. | Buy | 1,000 | $10.58 | $10.6K Buy | Form 4 ↗ |
| Apr 15, 2026 | Jean Jacques Bienaime Director | KROS Keros Therapeutics, Inc. | Buy | 1,000 | $11.70 | $11.7K Buy | Form 4 ↗ |
| Mar 9, 2026 | Jean Jacques Bienaime Director | KROS Keros Therapeutics, Inc. | Buy | 2,000 | $11.21 | $22.4K Buy | Form 4 ↗ |
| Feb 19, 2026 | Jasbir Seehra CHIEF EXECUTIVE OFFICER, Director | KROS Keros Therapeutics, Inc. | Sale | 7,015 | $16.17 | $113.4K Sale | Form 4 ↗ |
| Feb 18, 2026 | Esther Cho SVP, General Counsel | KROS Keros Therapeutics, Inc. | Sale | 4,745 | $16.35 | $77.6K Sale | Form 4 ↗ |
| Feb 18, 2026 | Lorena Raquel Lerner Chief Science Officer | KROS Keros Therapeutics, Inc. | Sale | 3,873 | $16.35 | $63.3K Sale | Form 4 ↗ |
| Feb 18, 2026 | Keith Regnante CHIEF FINANCIAL OFFICER | KROS Keros Therapeutics, Inc. | Sale | 4,739 | $16.35 | $77.5K Sale | Form 4 ↗ |
| Oct 15, 2025 | Pontifax (China) IV L.P. 10% owner | KROS Keros Therapeutics, Inc. | Sale | 155,262 | $17.75 | $2.8M Sale | Form 4 ↗ |
| Oct 15, 2025 | Pontifax (China) IV L.P. 10% owner | KROS Keros Therapeutics, Inc. | Sale | 1.23M | $17.75 | $21.8M Sale | Form 4 ↗ |
| Oct 15, 2025 | Pontifax (China) IV L.P. 10% owner | KROS Keros Therapeutics, Inc. | Sale | 1.12M | $17.75 | $19.9M Sale | Form 4 ↗ |
| Oct 15, 2025 | Pontifax (China) IV L.P. 10% owner | KROS Keros Therapeutics, Inc. | Sale | 2.28M | $17.75 | $40.6M Sale | Form 4 ↗ |
| Oct 15, 2025 | Daniel Schneeberger 10% owner | KROS Keros Therapeutics, Inc. | Sale | 743,358 | $17.75 | $13.2M Sale | Form 4 ↗ |
| Oct 15, 2025 | Daniel Schneeberger 10% owner | KROS Keros Therapeutics, Inc. | Sale | 254,669 | $17.75 | $4.5M Sale | Form 4 ↗ |
| Oct 15, 2025 | Daniel Schneeberger 10% owner | KROS Keros Therapeutics, Inc. | Sale | 4.39M | $17.75 | $77.9M Sale | Form 4 ↗ |
| Apr 9, 2025 | ADAR1 Partners, LP 10% owner | KROS Keros Therapeutics, Inc. | Buy | 74,333 | $10.33 | $767.9K Buy | Form 4 ↗ |
| Apr 9, 2025 | ADAR1 Partners, LP 10% owner | KROS Keros Therapeutics, Inc. | Buy | 500,000 | $10.33 | $5.2M Buy | Form 4 ↗ |
| Apr 9, 2025 | ADAR1 Partners, LP 10% owner | KROS Keros Therapeutics, Inc. | Buy | 325,000 | $9.86 | $3.2M Buy | Form 4 ↗ |
| Apr 9, 2025 | ADAR1 Partners, LP 10% owner | KROS Keros Therapeutics, Inc. | Buy | 16,365 | $9.40 | $153.8K Buy | Form 4 ↗ |
| Apr 9, 2025 | ADAR1 Partners, LP 10% owner | KROS Keros Therapeutics, Inc. | Buy | 18,560 | $9.40 | $174.5K Buy | Form 4 ↗ |
| Jan 4, 2024 | Keith Regnante CHIEF FINANCIAL OFFICER | KROS Keros Therapeutics, Inc. | Sale | 40,000 | $45.29 | $1.8M Sale | Form 4/A ↗ |
31 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 6:01 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances